Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))

Brian Feagan, William Sandborn, Bosny Pierre-Louis, Christopher Fourment, Maria Abreu

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)E7
JournalInflammatory bowel diseases
Volume20
Issue number2
DOIs
StatePublished - Feb 1 2014

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this